Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Nov 30

PMID 31781493

Citations 23

Authors

Mubalake Abudoureyimu

Yongting Lai

Chuan Tian

Ting Wang

Rui Wang

Xiaoyuan Chu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide, particularly in China. Despite the development of HCC treatment strategies, the survival rate remains unpleasant. Gene-targeted oncolytic viral therapy (GTOVT) is an emerging treatment modality-a kind of cancer-targeted therapy-which creates viral vectors armed with anti-cancer genes. The adenovirus is a promising agent for GAOVT due to its many advantages. In spite of the oncolytic adenovirus itself, the host immune response is the determining factor for the anti-cancer efficacy. In this review, we have summarized recent developments in oncolytic adenovirus engineering and the development of novel therapeutic genes utilized in HCC treatment. Furthermore, the diversified roles the immune response plays in oncolytic adenovirus therapy and recent attempts to modulate immune responses to enhance the anti-cancer efficacy of oncolytic adenovirus have been discussed.

Citing Articles

The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.

Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou E, Sivaramakrishnan G Int J Mol Sci. 2024; 25(23).

PMID: 39684701 PMC: 11641702. DOI: 10.3390/ijms252312990.

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.

Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner.

Zeng M, Zhang W, Li Y, Yu L Biomark Res. 2024; 12(1):36.

PMID: 38528632 PMC: 10962185. DOI: 10.1186/s40364-024-00581-1.

Immune landscape and response to oncolytic virus-based immunotherapy.

Lin C, Teng W, Tian Y, Li S, Xia N, Huang C Front Med. 2024; 18(3):411-429.

PMID: 38453818 DOI: 10.1007/s11684-023-1048-0.

The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.

Chen F, Jiang J, Liu D, Li H, Dong L, Song Y J Mol Histol. 2024; 55(1):83-96.

PMID: 38165571 DOI: 10.1007/s10735-023-10173-2.

References

Li K, Li X, Wu Z, Zheng L, Cui Y, Wang J . Adenovirus encoding XAF-1 and TNF‑α in the same open reading frame efficiently inhibits hepatocellular cancer cells. Mol Med Rep. 2016; 13(6):5169-76. DOI: 10.3892/mmr.2016.5193. View

Harrington K, Freeman D, Kelly B, Harper J, Soria J . Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019; 18(9):689-706. DOI: 10.1038/s41573-019-0029-0. View

El-Shemi A, Ashshi A, Na Y, Li Y, Basalamah M, Al-Allaf F . Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res. 2016; 35:74. PMC: 4859966. DOI: 10.1186/s13046-016-0353-8. View

Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E . The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A. 1992; 89(16):7742-6. PMC: 49787. DOI: 10.1073/pnas.89.16.7742. View

Szymczak A, Workman C, Wang Y, Vignali K, Dilioglou S, Vanin E . Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004; 22(5):589-94. DOI: 10.1038/nbt957. View

Xie W, Hao J, Zhang K, Fang X, Liu X . Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion. Biochem Biophys Res Commun. 2018; 503(4):2758-2763. DOI: 10.1016/j.bbrc.2018.08.036. View

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

Sharon D, Schumann M, MacLeod S, McPherson R, Chaurasiya S, Shaw A . 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells. PLoS One. 2013; 8(6):e65222. PMC: 3672087. DOI: 10.1371/journal.pone.0065222. View

Gopalan B, Litvak A, Sharma S, Mhashilkar A, Chada S, Ramesh R . Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res. 2005; 65(8):3017-24. DOI: 10.1158/0008-5472.CAN-04-3758. View

10.

Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F . VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014; 24(3):331-43. PMC: 3945886. DOI: 10.1038/cr.2014.10. View

11.

Goradel N, Mohajel N, Malekshahi Z, Jahangiri S, Najafi M, Farhood B . Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol. 2018; 234(6):8636-8646. DOI: 10.1002/jcp.27850. View

12.

Marelli G, Howells A, Lemoine N, Wang Y . Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Front Immunol. 2018; 9:866. PMC: 5932159. DOI: 10.3389/fimmu.2018.00866. View

13.

Kelly E, Russell S . MicroRNAs and the regulation of vector tropism. Mol Ther. 2008; 17(3):409-16. PMC: 2835080. DOI: 10.1038/mt.2008.288. View

14.

Oliva S, Gambella M, Boccadoro M, Bringhen S . Systemic virotherapy for multiple myeloma. Expert Opin Biol Ther. 2017; 17(11):1375-1387. DOI: 10.1080/14712598.2017.1364359. View

15.

Kaufmann J, Nettelbeck D . Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol Med. 2012; 18(7):365-76. DOI: 10.1016/j.molmed.2012.04.008. View

16.

Weydert C, Roling B, Liu J, Hinkhouse M, Ritchie J, Oberley L . Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther. 2003; 2(4):361-9. View

17.

Boyd J, Malstrom S, Subramanian T, Venkatesh L, Schaeper U, Elangovan B . Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell. 1994; 79(2):341-51. DOI: 10.1016/0092-8674(94)90202-x. View

18.

Shi Y, Han Y, Xie F, Wang A, Feng X, Li N . ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. J Cell Mol Med. 2014; 19(3):535-43. PMC: 4369811. DOI: 10.1111/jcmm.12435. View

19.

Li N, Zhou J, Weng D, Zhang C, Li L, Wang B . Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2007; 13(19):5847-54. DOI: 10.1158/1078-0432.CCR-07-0499. View

20.

Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L . a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6(8):879-85. DOI: 10.1038/78638. View